Get the Stockscreener App
192.03
0.03%
-0.05
Pre-market:
190.51
-1.52
-0.79%
Biogen Inc stock is traded at $192.03, with a volume of 795.15K.
It is down -0.03% in the last 24 hours and up +16.11% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$192.08
Open:
$190.78
24h Volume:
795.15K
Relative Volume:
0.42
Market Cap:
$28.18B
Revenue:
$9.69B
Net Income/Loss:
$1.61B
P/E Ratio:
17.51
EPS:
10.9652
Net Cash Flow:
$2.26B
1W Performance:
-2.28%
1M Performance:
+16.11%
6M Performance:
+38.16%
1Y Performance:
+40.09%
1-Day Range:
$189.95
$192.59
1-Week Range:
$189.95
$200.29
52-Week Range:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.03 | 28.19B | 9.69B | 1.61B | 2.26B | 10.97 |
|
LLY
Lilly Eli Co
|
1,009.52 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.49 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.81 | 396.51B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
204.20 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.67 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Dementia Treatment Market Booming with Rapid Growth Through - openPR.com
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative - CSRwire
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative - CSRwire
Biogen Included in 2022 Bloomberg Gender-Equality Index - CSRwire
Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB - MarketBeat
Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
Beyond The Numbers: 21 Analysts Discuss Biogen Stock - Benzinga
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst - TipRanks
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra - GuruFocus
Barclays initiates Biogen stock coverage with $185 price target - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB - MarketBeat
New Biogen Chair Freire May Recast Partnerships And Capital Priorities - Yahoo Finance
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection - TradingView
Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Newswire Canada
Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year - Yahoo Finance
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism - simplywall.st
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Therapeutics Market to Reach USD 46.22 - openPR.com
Aberdeen Group plc Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Biogen head of pharm ops Murphy buys $585 in stock By Investing.com - Investing.com Canada
Biogen head of pharm ops Murphy buys $585 in stock - Investing.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush lifts PT on Biogen Inc. (BIIB) to $187 from $178 – here’s why - MSN
5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC - MarketBeat
Biogen Stock Performance 2026 | Financial Results & Analyst RatingsNews and Statistics - IndexBox
What Price Targets Have Wall Street Analysts Set for Biogen Shares? - Bitget
What Are Wall Street Analysts' Target Price for Biogen Stock? - Barchart.com
AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Appoints Dr. Gabriela Freire as Board Chair While Immunic Inc. Searches for New CEO - geneonline.com
Early Diagnosis Kit for Alzheimer's Disease Market Outlook - openPR.com
Rhumbline Advisers Has $40.51 Million Position in Biogen Inc. $BIIB - MarketBeat
What are Biogen Inc.’s recent SEC filings showingMarket Risk Report & Growth Oriented Trade Recommendations - mfd.ru
Biogen’s New Therapies Surpass US$1 Billion In Sales Might Change The Case For Investing In BIIB - simplywall.st
LSV Asset Management Grows Position in Biogen Inc. $BIIB - MarketBeat
Oppenheimer & Co. Inc. Has $1.91 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Clinically Isolated Syndrome Treatment Market Size 2030 US$ 2.4 - openPR.com
BIIB: Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs - TradingView
Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus - MarketBeat
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why - Insider Monkey
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178Here's Why - Finviz
Is Biogen (NASDAQ:BIIB) Using Too Much Debt? - 富途牛牛
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings - simplywall.st
Krilogy Financial LLC Invests $1.18 Million in Biogen Inc. $BIIB - MarketBeat
Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
The 5 Most Interesting Analyst Questions From Biogen's Q4 Earnings Call - Finviz
Biogen Inc. $BIIB Shares Sold by Illinois Municipal Retirement Fund - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):